UPC news – the Milan section opens its doors

UPC News 27 June 2024

As of today (27 June 2024) the Milan section of the central division of the Unified Patent Court (UPC) has officially opened its doors.

The Milan section joins Paris and Munich in the central division of the UPC. Cases before the central division will be split between the three locations as per Annex II of the UPCA, as amended by Article 1 paragraph 2 of the Decision of the Administrative Committee (dated 26 June 2023). The Milan section will hear cases pertaining to IPC class A (Human Necessities) without Supplementary Protection Certificates.

The Milan section will be presided over by Mr Andrea Postiglione, with judges Ms Anna-Lena Klein and Ms Marije Knijff.

For further commentary on the UPC, read the latest from our team here.

Relevant sectors

Food and beverage

Nutrition
Retail
Beverages

Artificial intelligence and machine learning

Consumer goods and retail

Anti-counterfeit devices
Moda
Health, fitness and sport
Beauty
Fashion
Luxury goods
Retail
Household goods

Trade marks

Mechanical products
Services
Telecommunications
Financial services
Cosmetics and perfumery
Consumer goods

Chemicals

Agrochemicals
Catalysts
Dispersions and colloids
Lubricants
Polymers and plastics

Materials

Advanced materials
Composite materials
Metallurgy and alloys
Nanotechnology

Industrial manufacturing and processing

Packaging
Polymers and plastics
Printing tech
Additive manufacturing
Coatings
Construction

Electronics and electrical devices

Restaurants and bars
Travel and leisure
Testing systems, control systems, signal processing
Computer and IT architecture and system design
Medical devices
Optics
Robotics
Scientific instruments
Semiconductor devices
Wearable tech and human interfaces

Communications and networks

Oceanography, marine
Cloud computing
Internet of things (IOT)
Wired and wireless networks

Energy and green technologies

Solar power
Wind turbines
Water, oil and gas, nuclear, fusion, fission
Clean air
Fuel cells and battery technology
Renewables and recycling
Biofuels

Automotive

Autonomous vehicles
Electric vehicles
Engines

Aerospace

Commercial aviation
Defence and security
Space and satellites
Unmanned aerial vehicles

Pharmaceuticals

Pharmaceuticalsceutical formulations
Diagnostics
Drug delivery
Generic market entry
Medicinal chemistry
Methods of production and synthesis
Personalised medicine/disease biomarkers
Pharmaceutical formulations
Polymorphs
Small molecule pharmaceuticals
Supplementary protection certificates (SPCs)

Biotechnology

Bioinformatics
Next generation sequencing
Women’s health products
Vaccinology (e.g. viral vectors; mRNA vaccines)
Therapeutic antibodies
Synthetic biology
Stem cell therapies
Recombinant protein production and purification
Personalised medicine/disease biomarkers
Nucleic acid synthesis
Supplementary protection certificates (SPCs)
Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
GM crops
Genomic and molecular tools and methods
Gene editing (e.g. CRISPR)
Drug delivery
Biosimilars
Antibody manufacture and formulation
Antibody engineering

Medical devices and diagnostics

Immuno-oncology
Artificial intelligence
Devices
Diagnostic instruments
Digital health
Drug delivery
In vitro diagnostics
Medtech

Computing and software

Digital assistants, virtual assistants and software agents
Multimedia, audio/video processing and animation
Metaverse, virtual reality (VR) and augmented reality (AR)
Data management and storage, databases and data compression
Data and software security, cryptography and digital rights management (DRM)
Software applications and systems, mobile applications, user interfaces
Natural language processing
Search engines
Robotic process automation
Quantum computing
Motor capture
Machine vision
Fintech and adtech
Computer games
Communications and networks
Blockchain and distributed ledgers
Bioinformatics
Signal processing
Artificial intelligence and machine learning